{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:42:48Z","timestamp":1777293768882,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2025JJ60564"],"award-info":[{"award-number":["2025JJ60564"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["2024JJ5598"],"award-info":[{"award-number":["2024JJ5598"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06620-7","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T06:43:50Z","timestamp":1758350630000},"page":"5507-5512","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Imatinib and blinatumomab successfully rescued a pediatric B-ALL patient with TERF2::PDGFRB fusion resistant to dasatinib and chemotherapy"],"prefix":"10.1007","volume":"104","author":[{"given":"Fanghua","family":"Ye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangchun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"6620_CR1","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391\u20132405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544","journal-title":"Blood"},{"key":"6620_CR2","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/asheducation-2016.1.561","volume":"2016","author":"TH Tran","year":"2016","unstructured":"Tran TH, Loh ML (2016) Ph-like acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016:561\u2013566","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"6620_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1056\/NEJMoa1403088","volume":"371","author":"KG Roberts","year":"2014","unstructured":"Roberts KG, Li Y, Payne-Turner D et al (2014) Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med 371:1005\u20131015. https:\/\/doi.org\/10.1056\/NEJMoa1403088","journal-title":"N Engl J Med"},{"key":"6620_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1182\/blood.2023023153","volume":"145","author":"TH Tran","year":"2025","unstructured":"Tran TH, Tasian SK (2025) How i treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults. Blood 145:20\u201334. https:\/\/doi.org\/10.1182\/blood.2023023153","journal-title":"Blood"},{"key":"6620_CR5","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1007\/s00018-020-03753-y","volume":"78","author":"E Guerit","year":"2021","unstructured":"Guerit E, Arts F, Dachy G, Boulouadnine B, Demoulin JB (2021) PDGF receptor mutations in human diseases. Cell Mol Life Sci 78:3867\u20133881. https:\/\/doi.org\/10.1007\/s00018-020-03753-y","journal-title":"Cell Mol Life Sci"},{"key":"6620_CR6","doi-asserted-by":"publisher","first-page":"3902","DOI":"10.1002\/cncr.35481","volume":"130","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wang Y, Tian X et al (2024) Delineation of features, responses, outcomes, and prognostic factors in pediatric PDGFRB-positive acute lymphoblastic leukemia patients: a retrospective multicenter study. Cancer 130:3902\u20133912. https:\/\/doi.org\/10.1002\/cncr.35481","journal-title":"Cancer"},{"key":"6620_CR7","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S1470-2045(08)70339-5","volume":"10","author":"ML Den Boer","year":"2009","unstructured":"Den Boer ML, van Slegtenhorst M, De Menezes RX et al (2009) A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 10:125\u2013134. https:\/\/doi.org\/10.1016\/S1470-2045(08)70339-5","journal-title":"Lancet Oncol"},{"key":"6620_CR8","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.3324\/haematol.2020.247973","volume":"106","author":"S Chiaretti","year":"2021","unstructured":"Chiaretti S, Messina M, Della SI et al (2021) Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. HAEMATOLOGICA 106:1559\u20131568","journal-title":"HAEMATOLOGICA"},{"key":"6620_CR9","doi-asserted-by":"publisher","unstructured":"Heilmann AM, Schrock AB, He J et al (2017) Novel PDGFRB fusions in childhood B- and T-acute lymphoblastic leukemia, vol 31. LEUKEMIA, pp 1989\u20131992. https:\/\/doi.org\/10.1038\/leu.2017.161","DOI":"10.1038\/leu.2017.161"},{"key":"6620_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3785\/j.issn.1008-9292.2008.02.012","volume":"37","author":"XH Chen","year":"2008","unstructured":"Chen XH, Tong Y, Xu WL, Jin J, Qian WB (2008) [Expression of telomere binding factor 2 (TRF2) on leukemia cell lines and primary leukemia cells]. Zhejiang Da Xue Xue Bao Yi Xue Ban 37:170\u2013175. https:\/\/doi.org\/10.3785\/j.issn.1008-9292.2008.02.012","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"6620_CR11","doi-asserted-by":"publisher","first-page":"e18114","DOI":"10.1111\/jcmm.18114","volume":"28","author":"GF Xu","year":"2024","unstructured":"Xu GF, Zeng Z, Zhang ZB et al (2024) The novel TERF2::PDGFRB fusion gene enhances tumorigenesis via PDGFRB\/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL. J CELL MOL MED 28:e18114. 10.1111\/ jcmm.18114","journal-title":"J CELL MOL MED"},{"key":"6620_CR12","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Foa","year":"2020","unstructured":"Foa R, Bassan R, Vitale A et al (2020) Dasatinib-Blinatumomab for Ph-Positive acute lymphoblastic leukemia in adults. N Engl J Med 383:1613\u20131623. https:\/\/doi.org\/10.1056\/NEJMoa2016272","journal-title":"N Engl J Med"},{"key":"6620_CR13","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1016\/S2352-3026(22)00319-2","volume":"10","author":"E Jabbour","year":"2023","unstructured":"Jabbour E, Short NJ, Jain N et al (2023) Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10:e24\u2013e34. https:\/\/doi.org\/10.1016\/S2352-3026(22)00319-2","journal-title":"Lancet Haematol"},{"key":"6620_CR14","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/JCO.23.01392","volume":"42","author":"A Hodder","year":"2024","unstructured":"Hodder A, Mishra AK, Enshaei A et al (2024) Blinatumomab for first-line treatment of children and young persons with B-ALL. J Clin Oncol 42:907\u2013914. https:\/\/doi.org\/10.1200\/JCO.23.01392","journal-title":"J Clin Oncol"},{"key":"6620_CR15","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31785","volume":"72","author":"J Fu","year":"2025","unstructured":"Fu J, Zong W, Kang M, Fang Y, Wang Y (2025) Overcoming chemotherapy resistance in EBF1-PDGFRB-positive B-ALL: a novel therapeutic approach using dasatinib and blinatumomab. Pediatr Blood Cancer 72:e31785. https:\/\/doi.org\/10.1002\/pbc.31785","journal-title":"Pediatr Blood Cancer"},{"key":"6620_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ajh.26352","volume":"97","author":"W Shomali","year":"2022","unstructured":"Shomali W, Gotlib J (2022) World health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97:129\u2013148. https:\/\/doi.org\/10.1002\/ajh.26352","journal-title":"Am J Hematol"},{"key":"6620_CR17","doi-asserted-by":"publisher","DOI":"10.1101\/mcs.a004937","author":"WY Lee","year":"2020","unstructured":"Lee WY, Pfau RB, Choi SM et al (2020) The diagnostic challenges and clinical course of a myeloid\/lymphoid neoplasm with eosinophilia and ZBTB20-JAK2 gene fusion presenting as B-lymphoblastic leukemia. Cold Spring Harb Mol Case Stud. https:\/\/doi.org\/10.1101\/mcs.a004937","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"6620_CR18","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00428-022-03402-8","volume":"482","author":"A Tzankov","year":"2023","unstructured":"Tzankov A, Reichard KK, Hasserjian RP, Arber DA, Orazi A, Wang SA (2023) Updates on eosinophilic disorders. Virchows Arch 482:85\u201397. https:\/\/doi.org\/10.1007\/s00428-022-03402-8","journal-title":"Virchows Arch"},{"issue":"9","key":"6620_CR19","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1007\/s00277-023-05236-z","volume":"102","author":"KW Tan","year":"2023","unstructured":"Tan KW, Zhu YY, Qiu QC et al (2023) Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review. ANN HEMATOL 102(9):2397\u20132402. https:\/\/doi.org\/10.1007\/s00277-023-05236-z","journal-title":"ANN HEMATOL"},{"key":"6620_CR20","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P et al (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino) thiazole-5-carboxamide (BMS-354825), a dual src\/abl kinase inhibitor with potent antitumor activity in preclinical assays. J MED CHEM 47:6658\u20136661. https:\/\/doi.org\/10.1021\/jm049486a","journal-title":"J MED CHEM"},{"key":"6620_CR21","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1182\/blood.2023023120","volume":"143","author":"I van Outersterp","year":"2024","unstructured":"van Outersterp I, Tasian SK, Reichert C et al (2024) Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: the role of kinase type and SH3 domain. Blood 143:2178\u20132189. https:\/\/doi.org\/10.1182\/blood.2023023120","journal-title":"Blood"},{"key":"6620_CR22","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1182\/blood-2017-11-817510","volume":"131","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Gao Y, Zhang H et al (2018) PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia. Blood 131:2256\u20132261. https:\/\/doi.org\/10.1182\/blood-2017-11-817510","journal-title":"Blood"},{"key":"6620_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1383419","volume":"14","author":"L Feng","year":"2024","unstructured":"Feng L, Zhang H, Liu T (2024) Multifaceted roles of IKZF1 gene, perspectives from bench to bedside. FRONT ONCOL 14:1383419. https:\/\/doi.org\/10.3389\/fonc.2024.1383419","journal-title":"FRONT ONCOL"},{"key":"6620_CR24","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1097\/MPH.0000000000001743","volume":"43","author":"Y Sakurai","year":"2021","unstructured":"Sakurai Y, Sarashina T, Toriumi N et al (2021) B-cell precursor-acute lymphoblastic leukemia with EBF1-PDGFRB fusion treated with hematopoietic stem cell transplantation and imatinib: a case report and literature review. J Pediatr Hematol Oncol 43:e105\u2013e108. https:\/\/doi.org\/10.1097\/MPH.0000000000001743","journal-title":"J Pediatr Hematol Oncol"},{"key":"6620_CR25","doi-asserted-by":"publisher","first-page":"e529","DOI":"10.1016\/S2352-3026(","volume-title":"Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial","author":"E Jabbour","year":"2025","unstructured":"Jabbour E, Lussana F, Martinez-Sanchez P et al (2025) Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1\/2 trial, vol 12. LANCET HAEMATOL, pp e529\u2013e541. https:\/\/doi.org\/10.1016\/S2352-3026("},{"key":"6620_CR26","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1007\/s11912-025-01683-1","volume":"27","author":"V Agrawal","year":"2025","unstructured":"Agrawal V, Koller P, Stein A, Pullarkat V, Aldoss I (2025) The role of transplant for Philadelphia-positive B-cell acute lymphoblastic leukemia in 2025. Curr Oncol Rep 27:748\u2013760. https:\/\/doi.org\/10.1007\/s11912-025-01683-1","journal-title":"Curr Oncol Rep"},{"key":"6620_CR27","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1016\/j.jtct.2024.11.007","volume":"30","author":"JC Molina","year":"2024","unstructured":"Molina JC (2024) Hematopoietic cell transplantation in CR1 may help mitigate the adverse outcomes of Ph-like B-ALL in adult patients. Transpl Cell Ther 30:1118\u20131120. https:\/\/doi.org\/10.1016\/j.jtct.2024.11.007","journal-title":"Transpl Cell Ther"},{"key":"6620_CR28","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/j.bbmt.2019","volume":"26","author":"FR El","year":"2020","unstructured":"El FR, Savani B, Mohty M, Aljurf M (2020) Hematopoietic cell transplant consideration for Philadelphia Chromosome-Like acute lymphoblastic leukemia patients. Biol Blood Marrow Transpl 26:e16\u2013e20. https:\/\/doi.org\/10.1016\/j.bbmt.201908.010","journal-title":"Biol Blood Marrow Transpl"},{"key":"6620_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2021.101242","volume":"34","author":"I Aldoss","year":"2021","unstructured":"Aldoss I, Advani AS (2021) Have any strategies in Ph-like ALL been shown to be effective? Best Pract Res Clin Haematol 34:101242. https:\/\/doi.org\/10.1016\/j.beha.2021.101242","journal-title":"Best Pract Res Clin Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06620-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06620-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06620-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T08:18:57Z","timestamp":1763194737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06620-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6620"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06620-7","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"assertion":[{"value":"22 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient provided consent for the publication of this case report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The ethics committee of the Xiangya Hospital Central South University approved this study. Informed consent was obtained from the patient following the Declaration of Helsinki. All patient data were anonymized and de-identified before analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}